# Han Han

List of Publications by Year
in descending order

| 9 papers | 608 citations | 1306789 7 h-index | 1719596 7 g-index |
|---|---|---|---|
| 9 all docs | 9 docs citations | 9 times ranked | 1164 citing authors |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1 | Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Cancer Discovery, 2022, 12, 47-61. | 7.7 | 58 |
| 2 | Loss of <i>TSC1/TSC2</i> sensitizes immune checkpoint blockade in non–small cell lung cancer. Science Advances, 2022, 8, eabi9533. | 4.7 | 16 |
| 3 | Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 371-380. | 3.0 | 153 |
| 4 | Response to Cottu, Bozec, Basse, and Paoletti. Journal of the National Cancer Institute, 2021, 113, 344-345. | 3.0 | 0 |
| 5 | Recent advances in preclinical models for lung squamous cell carcinoma. Oncogene, 2021, 40, 2817-2829. | 2.6 | 26 |
| 6 | ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. Nature Cancer, 2021, 2, 503-514. | 5.7 | 72 |
| 7 | Response to Huang, Rivero-Hinojosa, Ma, et al. Journal of the National Cancer Institute, 2021, 113, 1111-1112. | 3.0 | 0 |
| 8 | CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9. | 7.7 | 138 |
| 9 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7. | 7.7 | 145 |